Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

PHASE4CompletedINTERVENTIONAL
Enrollment

329

Participants

Timeline

Start Date

February 28, 2002

Study Completion Date

April 30, 2006

Conditions
Ocular HypertensionGlaucoma, Open-Angle
Interventions
DRUG

latanoprost 0.005% (Xalatan)

Trial Locations (27)

15110

Pfizer Investigational Site, Lahti

20100

Pfizer Investigational Site, Turku

33100

Pfizer Investigational Site, Tampere

60100

Pfizer Investigational Site, Seinäjoki

70100

Pfizer Investigational Site, Kuopio

70361

Pfizer Investigational Site, Örebro

96200

Pfizer Investigational Site, Rovaniemi

Unknown

Pfizer Investigational Site, Ekenäs

Pfizer Investigational Site, Linköping

Pfizer Investigational Site, Mölndal

Pfizer Investigational Site, Nyköping

Pfizer Investigational Site, Stockholm

Pfizer Investigational Site, Uppsala

00100

Pfizer Investigational Site, Helsinki

00700

Pfizer Investigational Site, Helsinki

551 85

Pfizer Investigational Site, Jönköping

652 20

Pfizer Investigational Site, Karlstad

291 31

Pfizer Investigational Site, Kristianstad

771 81

Pfizer Investigational Site, Ludvika

131 83

Pfizer Investigational Site, Nacka

601 82

Pfizer Investigational Site, Norrköping

602 36

Pfizer Investigational Site, Norrköping

151 72

Pfizer Investigational Site, Seinajoki

113 22

Pfizer Investigational Site, Stockholm

851 86

Pfizer Investigational Site, Sundsvall

183 34

Pfizer Investigational Site, Täby

751 85

Pfizer Investigational Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY